News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 12, 2024

Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

Jason Porter, MD, outlines the most significant unaddressed challenges in treating and managing non-small cell lung cancer as the field approaches the American Society of Clinical Oncology's 2024 annual meeting.

Episodes in this series

This series features 1 KOL.

EP. 1 Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 2 ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC

Jason Porter, MD, an expert on lung cancer

EP. 3 Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 4 Insights from the TROPION-Lung05 Trial at ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 5 Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 6 ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

February 6th 2026

Acalabrutinib | Image Credit: © Сергей Шиманович-stocka.dobe.com.jpeg

Real-World Evidence Backs Acalabrutinib in CLL Care

ByMaggie L. Shaw

February 6th 2026

Debates at the International Stroke Conference 2026 centered on optimal treatment of ischemic stroke in the modern era. | Image credit: Aliaksandr Marko - stock.adobe.com

Is Less More After Thrombolysis? Debating Intensive Stroke Monitoring at ISC 2026

February 6th 2026

Dr Susan Vadaparampil

Linking Community Screening Programs to Cancer Centers Boosts Trial Diversity: Susan Vadaparampil, PhD, MPH

ByBrooke McCormick,Susan Vadaparampil, PhD, MPH

February 6th 2026

AJMC letter to the editor

Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis

ByFranco Nicolae Grados Rodriguez

February 6th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

5 Things to Know About the Oral GLP-1 Era

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text